A small trial that mixed diet, sleep, exercise, and personal treatment plans beat the top Alzheimer’s drugs by a wide margin. Here is what it really shows, and what it does not.

Nearly seven and a half million Americans are living with Alzheimer’s disease right now. One in nine people over 65 has it. Almost every one of those people has a family standing beside them, managing medications, driving them to appointments, and hoping for something that works better than what we have today. Care for people with Alzheimer’s and other dementias is expected to cost the country over 400 billion dollars this year alone.

For years, the best that medicine has offered is a way to slow the fall. Two newer drugs, Leqembi and Kisunla, are given by IV infusion and cost tens of thousands of dollars a year. They can slow decline a bit, but they don’t stop it, and they do not restore memory. A recent review of the evidence found their effect on daily function was small at best. The drugs also carry real risks, including brain swelling and bleeding, in somewhere between 3 and 6 out of every 100 people treated.

So, when a new study came out in December 2025 claiming that patients got better instead of just declining more slowly, it caught a lot of attention. The study was led by Dr. Dale Bredesen and a team of physicians across six clinics in California, Florida, Ohio, and Tennessee. It has not yet been reviewed and peer-reviewed by other scientists, which matters, and we will come back to that. But it is worth understanding what they did and what they found.

What the Researchers Actually Did

The study included 73 people between the ages of 45 and 76, all dealing with early memory problems or mild dementia, not advanced Alzheimer’s. About two-thirds were randomly placed in a group that received a personalized treatment plan. The rest received the usual care a memory clinic offers today, mostly monitoring, and sometimes one of the newer drugs. Random assignment is what makes this study stronger than the personal success stories you may have read about online.

The personalized group didn’t get one pill aimed at one target. Instead, each patient went through a deep round of testing. Researchers checked blood sugar, cholesterol, hormone levels, vitamin levels, sleep quality, and gut health. They tested for hidden infections, including Lyme disease and old cases of herpes virus, both linked to memory problems in some patients. They looked for toxins from mold or metals like mercury and checked genes that can affect memory.

Then each patient got a plan developed around whatever showed up as a problem for them, rather than a one-size-fits-all prescription. Common pieces included a diet low in sugar and processed foods, daily exercise, better sleep habits, stress management, computer-based brain training, and treatment for any infections, hormone gaps, or toxin exposure the tests turned up. A team of a physician, health coach, nutritionist, and fitness trainer checked in with each patient regularly over nine months, then tested everyone again.

What They Found

The people in the personalized program improved on memory tests, on tests of quick thinking, and on tests of planning and follow-through. Their study partners, usually a spouse or adult child, also reported noticing a noticeable improvement in daily life, things like remembering appointments or following a conversation. The comparison group, receiving standard care, mostly stayed the same or got slightly worse over the same nine months.

Blood pressure, weight, blood sugar, and cholesterol also improved in the personalized group. Some patients were able to come off blood pressure or diabetes medication because their numbers improved so much.

When researchers compared the size of the improvement to the two approved Alzheimer’s drugs, the personalized approach showed a bigger effect, by several times over, than either drug did in its own studies.

That is genuinely encouraging news. But a full picture means looking at what did not improve, too. Brain scans measuring brain size showed no actual difference between the two groups. Blood tests that track Alzheimer’s disease activity in the body barely moved. And one well-known cognitive test used across the country, called the MoCA, showed only a small difference between the two groups, smaller than the other tests found. That gap between the different tests is one reason careful readers of this study are asking for more proof before calling it settled.

What This Means for You, and What It Does Not

Here is the honest, realistic version. This was a small study of 73 people, run at clinics that already specialize in this kind of treatment. It was not a double-blind study, meaning patients and their doctors knew who was getting which treatment, and that can shape how people report feeling and behaving. It has not yet passed the review other independent scientists give a study before it is considered settled science. Some physicians and Alzheimer’s organizations have raised concerns for years about this general approach, saying earlier versions of it relied on personal success stories rather than controlled studies like this one, and that families were sometimes given false hope and a large bill.

It is also demanding, in a way worth being honest about. Patients followed a strict diet, exercised most days of the week, slept on a fixed schedule, trained their brain daily on a computer, and worked closely with a team that included a physician, a health coach, a nutritionist, and a fitness trainer. That is not something most families can access or afford right now, and not something every patient will be able to stick with for nine months, especially someone already struggling with memory and follow-through.

What is realistic and possible is this. For people in the earliest stages of memory loss, addressing the whole body, sleep, blood sugar, hidden infections, stress, and hormones, alongside the brain itself, appears to help, and in this study it helped more than either approved drug did in its own trials. That lines up with a smaller, earlier study from the same research group. It does not mean Alzheimer’s has a cure. It does not mean this will work the same way for someone already in moderate or severe dementia, since this study did not include those patients. And it does not mean anyone should try to put this plan together alone, since pieces like hormone treatment or antibiotics for a hidden infection need a doctor watching closely.

Desperation and some scientific evidence may push people to believe that if they incorporate these things into a routine within their home, it may be helpful. We do not encourage this type of activity because there are too many factors involved in this disorder, and following this protocol without professional guidance may prove futile and even harmful.

If you or someone you love is in the early stages of memory loss, this study is a real reason for hope, and a real reason to ask your physician for a full workup rather than settling for a prescription alone. Ask about your blood sugar, your sleep, your vitamin levels, and your stress. Ask whether hidden infections (UTIs) or hormone changes could be playing a part. And ask about a larger, more strictly controlled trial, since Bredesen’s team has said that is the next step, and that is the study that will really tell us how far this can go.

I once consulted at an upscale nursing home where an elderly woman was diagnosed with bipolar disorder, and they ordered an antipsychotic medication for her. It is not unusual for older women with urinary tract infections to exhibit symptoms that appear to be bipolar disorder. In this woman’s case, that was exactly what she had, not bipolar disorder.

Alzheimer’s has taken so much from so many families, and this study will not undo that. But it gives families something many of them have not had in a long time: real, careful evidence that decline does not always have to be the whole story, and a specific list of questions to bring to the next doctor’s appointment.